Metabolic biomarkers for chronic kidney disease

Breit, Marc; Weinberger, Klaus M.

doi:10.1016/j.abb.2015.07.018

Cited by 38 publications

(33 citation statements)

References 194 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite compelling examples of the use of genomics to support personalized medicine, genomics alone is unlikely to provide sufficient information regarding disease pathophysiology and prognosis. Indeed, in spite of other omics approaches, including transcriptomics and metabolomics, have emerged as powerful tools for developing novel biomarkers for CKD in recent years [86][87][88] , and proteomics remains the classic realm for biomarker discovery. In this respect, transcriptional, translational, and post-translational modifications, which cause functional changes to proteins and their function, represent another unexplored area.…”

Section: Towards Personalized Medicine: Future Prospects and Challengesmentioning

confidence: 99%

Genomic biomarkers for chronic kidney disease: the first step towards personalized medicine?

Cao¹,

Zhou²,

Liu³

2019

JTGG

View full text Add to dashboard Cite

With the prevalence of end stage renal disease steadily increasing, chronic kidney disease (CKD) represents an impending public healthcare challenge. Classical diagnostic biomarkers of CKD, including creatinine, have low sensitivity and specificity. Thus, novel diagnostic and prognostic biomarkers for patients at high risk of early-stage progression are urgently needed. Personalized medicine approaches generally stratify patients according to their biological or genomic make-up. Targeted clinical trials require more precise identification of these subgroups. The use of new biomarkers obtained via high-throughput technologies is expected in future, accompanied by vast improvements in computational power applied in genomics, proteomics, and metabolomics studies using biological fluids and renal biopsy tissue. Genomic biomarkers may not only provide additional information regarding the etiology and mechanisms underlying CKD progression, but may also enable early diagnosis and the selection of appropriate drugs, thereby personalizing therapy. This review discusses commonly used research methods in genomic medicine and summarizes currently available genomic biomarkers in inherited and acquired CKD.

show abstract

Section: Towards Personalized Medicine: Future Prospects and Challengesmentioning

confidence: 99%

Genomic biomarkers for chronic kidney disease: the first step towards personalized medicine?

Cao¹,

Zhou²,

Liu³

2019

JTGG

View full text Add to dashboard Cite

show abstract

“…Towards Metabolic Biomarkers for the Diagnosis and Prognosis of CKD http://dx.doi.org/10.5772/intechopen.80335 can only reflect one set of possible explanations for how metabolite concentrations are altered, and this shortcoming is primarily caused by difficult-to-avoid gaps in the documentation of most biomarker studies. Yet, the clinical experience from screening millions of newborns demonstrates that this particular limitation can be partly overcome: as soon as ratios of products and substrates of enzymatic reactions (or entire pathways) are analyzed instead of individual metabolite concentrations, the data are far less prone to all sorts of confounding factors such as dietary uptake and rather reflect the actual metabolic activity of the organism [66,[79][80][81].…”

Section: Metabolic Biomarker Candidates For Ckdmentioning

confidence: 99%

“…Towards Metabolic Biomarkers for the Diagnosis and Prognosis of CKD http://dx.doi.org/10.5772/intechopen.80335 may either mirror gaps in the analytical portfolio-after all, metabolomics is not a comprehensive omics discipline yet, and even less so if studies are based on a single technology or workflow-or a lack of pathway-oriented data analysis [79,80].…”

Section: Urea Cycle Alterations Nitric Oxide Synthesis and Polyaminmentioning

confidence: 99%

Towards Metabolic Biomarkers for the Diagnosis and Prognosis of CKD

Lundin¹,

Weinberger²

2018

Advances in Nephropathy

Self Cite

View full text Add to dashboard Cite

Chronic kidney disease, the gradual loss of renal function, is an increasingly recognized burden for patients and health care systems; globally, it has a high and rapidly growing prevalence, a significant mortality, and causes disproportionately high costs, particularly for hemodialysis and kidney transplantations. Yet, the available diagnostic tools are either impractical in clinical routine or have serious shortcomings preventing a well-informed disease management, although optimized treatment strategies with impressive benefits for patients have been established. Advances in bioanalytics have facilitated the identification of many genomic, proteomic, and metabolic biomarker candidates, some of which have been validated in independent cohorts. Summarizing the markers discovered so far, this chapter focuses on compounds or pathways, for which quantitative data, substantiating evidence from translational research, and a mechanistic understanding is available. Also, multiparametric marker panels have been suggested with promising diagnostic and prognostic performance in initial analyses, although the data basis from prospective trials is very limited. Large-scale studies, however, are underway and will validate certain sets of parameters and discard others. Finally, the path from clinical research to routine application is discussed, focusing on potential obstacles such as the use of mass spectrometry, and the feasibility of obtaining regulatory approval for metabolomics assays.

show abstract

“…CKD has a strong effect on general metabolism. Over the last decade, hundreds of publications reported that CKD affects amino acids and their metabolites, nitric oxide, polyamines, urea cycle metabolites, uric acid, acylcarnitines, and lipids [68,69]. The discovery of new biomarkers will generate a metabolomic signature that may improve early diagnosis of CKD, provide modern tools for monitoring progression of the disease and treatment response [70].…”

Section: Metabolomics and Lipidomicsmentioning

confidence: 99%

New perspectives on CKD-induced dyslipidemia

Bermúdez-López

Arroyo

Betriu

et al. 2017

Expert Opinion on Therapeutic Targets

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a world-wide health concern associated with a significantly higher cardiovascular morbidity and mortality. One of the principal cardiovascular risk factors is the lipid profile. CKD patients have a more frequent and progressive atheromatous disease that cannot be explained by the classical lipid parameters used in the daily clinical practice. Areas covered: The current review summarizes prevailing knowledge on the role of lipids in atheromathosis in CKD patients, including an overview of lipoprotein metabolism highlighting the CKD-induced alterations. Moreover, to obtain information beyond traditional lipid parameters, new state-of-the-art technologies such as lipoprotein subfraction profiling and lipidomics are also reviewed. Finally, we analyse the potential of new lipoprotein subclasses as therapeutic targets in CKD. Expert opinion: The CKD-induced lipid profile has specific features distinct from the general population. Besides quantitative alterations, renal patients have a plethora of qualitative lipid alterations that cannot be detected by routine determinations and are responsible for the excess of cardiovascular risk. New parameters, such as lipoprotein particle number and size, together with new biomarkers obtained by lipidomics will personalize the management of these patients. Therefore, nephrologists need to be aware of new insights into lipoprotein metabolism to improve cardiovascular risk assessment.

show abstract

Metabolic biomarkers for chronic kidney disease

Cited by 38 publications

References 194 publications

Genomic biomarkers for chronic kidney disease: the first step towards personalized medicine?

Genomic biomarkers for chronic kidney disease: the first step towards personalized medicine?

Towards Metabolic Biomarkers for the Diagnosis and Prognosis of CKD

New perspectives on CKD-induced dyslipidemia

Contact Info

Product

Resources

About